Introduction
Neutropenia is characterized by the reduction in white blood cells, with a neutrophil count of below 1.5x10 9 /L. The occurrence of this event varies from 16% to 81% among the patients who receive chemotherapy treatment (1) (2) (3) .
It is one of the principal adverse events (AE) of antineoplastic chemotherapy, and is the one which interferes most in the dosage of the chemotherapy agents. The occurrence of neutropenia is associated with an increase in mortality, morbidity and treatment costs, in addition to the impossibility of predicting which patients will present it (4) (5) .
The management of this chemotherapy-induced AE is administered in different ways in clinical practice. In general, the strategies are limited to the reduction of the dose of the chemotherapy agents, postponement between the cycles, and the use of colony-stimulating factors, although these are considered common clinical practices during the treatment of patients with primary breast cancer who present AEs, such as episodes of neutropenia (6) .
In spite of these strategies being widely used, clinical studies have shown that these modifications in the dosage or in the time scheduled can have as a consequence an inferior result in the final quality of the therapy (7) .
The efficacy of the assistance and the treatment given to the patient are fundamental for the quality of the health care. The occurrence of neutropenia indicates the need for nursing to define protocols for evaluation and follow-up, which includes the AEs, the degrees of compromise, and their management (1) .
The standards of neutropenia management vary from one health center to another. The development of nursing care protocols for the management of chemotherapy-induced neutropenia may allow more patients to benefit from: treatment with the complete dose undertaken within the schedule; reduction in variety of conduct in the assistance provided; promotion of the efficacious use of colony-stimulating factor; help in taking decisions regarding contradictory situations; and, principally, from improvement in the quality of the care for the patient, which leads to improvement in the results of the treatment (8) .
In the Gynecologic Oncology and Mastology outpatient clinic of the Hospital das Clínicas, University of São Paulo at Ribeirão Preto, Medical Faculty, of the (HCFMRP-USP), there are no nursing care protocols for attending women with gynecological or breast cancer during their treatment, which makes it difficult to standardize the guidance and information provided to the woman and her caregivers by the nursing team.
In the women's accounts, one can observe divergent or very often contradictory information. This hinders decision-making regarding the AEs of the chemotherapy treatment and the building of trust in the team. One may also note the absence of Brazilian studies directed at the management of neutropenia in the area of Nursing, as well as the implementation of specific protocols which help in improving the quality of the care given.
In the light of the above, this study's objective was to identify the prevalence of, and describe the management of, neutropenia throughout the chemotherapy treatment among women with breast cancer.
Method
This study is part of the project titled "Evaluation of the quality of life, anxiety, depression and toxicity to the chemotherapy treatment in women with breast cancer", Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO.
however, during the follow up, two women abandoned the chemotherapy treatment due to intolerance of the AEs, one requested to be excluded from the research, and one was diagnosed with metastasis. As a result, the sample was made up of 79 women. 
Results
Among the 79 women who participated, the age varied from 29 to 69 years old, with 34.2% falling into the age range of 51 to 60 years old, and 24.1% being aged below 40 years old. The participants' mean age was 48.4 years old, with a standard deviation of 9.67 years ( Table 1) .
Considering the clinical stages of breast cancer presented, the most observed was IIa in 25.3% of the women, followed by IIb and IIIb with a frequency of 21.5% for each one (Table 1) .
In relation to the therapy used, 50.6% of the women According to the data presented in Tables 3 and 4 Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO. 
Discussion
The development of myelosuppression during chemotherapy is influenced as much by the characteristics of the drugs used as by the conditions presented by the patient. Therefore, the association of myelotoxicity with the activity of the treatment is not always direct (9) .
Although the risk factors for neutropenia during chemotherapy treatment are not well defined, current studies point to: advanced age (≥65 years), female sex, low performance status and nutritional status, reduced body surface area, reduction in blood cell count prior to starting treatment (reduced number of lymphocytes and of hemoglobin) and previous involvement of the bone marrow (4, 10) .
The mean age of patients who participate in randomized clinical trials varies from 46 to 49 years old and is similar to that found in this study. However, it was possible to observe that the percentage of young women, from 31 to 40 years old, with mammary neoplasms has increased considerably, representing 22.8% in the sample studied. However, it stands out that in current studies the authors present the mean age of all the participants, without distinguishing between the age ranges which present neutropenia during the treatment or not (2, (11) (12) .
Regarding the choice, use and activity of the drugs, current data indicates that both for adjuvant and neoadjuvant treatment of breast cancer, chemotherapy regimens based on anthracyclines and taxanes are considered first choice. The introduction of the taxanes and the increase in the doses of the anthracyclines favor greater occurrence of myelotoxicities, resulting in the risk of febrile neutropenia and infections during the treatment (13) .
Neutropenia is the event which most influences the the reduction of the relative dose intensity, can limit the myelotoxicity, these actions can also impact negatively on the result of the treatment, and must be avoided (14) .
These delays or reductions of dose minimize the toxic sequelae of the treatment in patients whose blood count has not recovered appropriately. Such practices can have a significant impact on the survival results, in the same way that they reduce the intensity of the dose received. However, in order to obtain the maximum benefit from the chemotherapy treatment, the maintenance of the total dose calculated must be maintained as an important response factor to the treatment, as for every seven days of delay in the chemotherapy treatment, there is a reduction of approximately 5% of the intensity of the dose (6) .
A limited number of studies has shown that the absence of myelotoxicity during the chemotherapy is associated with a worse prognosis, which suggests that myelodepression may represent an important biological marker for the effect of the treatment. In addition to this, other researchers have emphasized the potential importance of adapting the chemotherapy dose based on the hematological toxicity, as the absence of this may be the result of underdosage. However, prospective studies are necessary to evaluate whether the dosage of the drug, guided by the occurrence of toxic effects, can improve the efficacy of standard regimes (10, 15) . Furthermore, the direct effects caused during the treatment, and the chemotherapy-induced neutropenia, have a detrimental effect on the patients' quality of life.
In clinical practice, so as to reduce the risk of infection, the neutropenic patients are instructed to follow strict advice, to avoid crowds, not to eat raw fruit/ vegetables and to monitor their temperature regularly. Running a fever with neutropenia is considered a medical emergency, and those who present this event generally need hospitalization and treatment with intravenous broad-spectrum antibiotics. This being so, the hospital well-being (16) (17) .
The cares and the person who is cared for (18) .
The need to establish efficient comprehensive care
for the oncological patient requires great mobilization of the entire health system, from the training of the professionals who shall provide the direct care to the infrastructure of the service that the patient shall use.
In a study which evaluated the management of the Nursing service in Brazilian public hospital institutions, the nursing team reports satisfaction regarding the care
given to the client, in relation to the qualification of the work, the dedication and the humanization in the attendance, and the communication. On the other hand, they feel uncomfortable because of the service, which lacks adequate facilities and sufficient human resources to care, as well as material in adequate quantities, and appropriate furniture (19) .
In research undertaken in 2008 in the same institution as the present study, which evaluated 72 women with breast cancer in neoadjuvant or adjuvant treatment, it was observed that of the 558 chemotherapy cycles undertaken, there were 152 delays between the cycles during the treatment. It is worth emphasizing that 82 of these delays were caused because of alterations detected in the hematological tests, while only six were caused by lack of a space in the chemotherapy center (20) .
Considering the data from the present study, one Technical Bases Manual, it is specified that adjuvant chemotherapy should be initiated, at the most, between 30 and 60 days post-surgery (21) . However, the time to be waited for undertaking the other chemotherapy cycles is not specified.
The current conditions of saturation in the public health services contribute to privation of citizenship, both of the service users, who receive health care which lacks quality, and of the health workers, who exercise their professional activities under inadequate working conditions. This process makes both parties vulnerable, although in different ways (22) .
The health organizations, among these the hospitals, as well as the various types of health professional, have invested in the search for new management strategies which may make it possible to conciliate the reduction of costs, the improvement of the quality of the services offered, and -principally -the clients' satisfaction. Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO.
Conclusion
The occurrence of neutropenia, observed in the present study, is in accordance with the results of international research. As this is characterized as one of the more common and serious AEs which can occur during antineoplastic chemotherapy, it is an important question to be investigated throughout the treatment. It is through investing in new management strategies able to achieve improvements in the work conditions of health professionals and in the organization of the public health system that the principal objective of the care for oncological patients shall be achieved:
the offering of quality care, protecting their autonomy, recognizing and valuing the professional who assists them, and establishing an empathetic relationship between both.
